Efficacy and safety of golimumab in patients with non-radiographic axial spondyloarthritis: a withdrawal and retreatment study (GO-BACK).

Cindy L J WeinsteinPaula Sliwinska-StanczykTomas HálaMarina StanislavAnjela TzontchevaRuji YaoYuliya BerdSean P CurtisGeorge Phillip

Published in: Rheumatology (Oxford, England) (2023)

Among participants with active nr-axSpA who attained inactive disease after 10 months of GLM treatment, continued GLM treatment is well tolerated and provides superior protection against disease flares compared with GLM withdrawal. (EudraCT: 2015-004020-65, registered on 30 March 2022; NCT: 03253796, registered on 18 August 2017).

Keyphrases

ankylosing spondylitis
combination therapy
rheumatoid arthritis
smoking cessation
ulcerative colitis